Get the Stockscreener App
3.01
0.00%
0.00
Pre-market:
3.06
0.05
+1.66%
Cabaletta Bio Inc stock is traded at $3.01, with a volume of 3.24M.
It is up +0.00% in the last 24 hours and down -9.06% over the past month.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
See More
Previous Close:
$3.01
Open:
$3.09
24h Volume:
3.24M
Relative Volume:
1.00
Market Cap:
$490.79M
Revenue:
-
Net Income/Loss:
$-175.43M
P/E Ratio:
-1.5251
EPS:
-1.9736
Net Cash Flow:
$-143.28M
1W Performance:
-5.94%
1M Performance:
-9.06%
6M Performance:
+25.94%
1Y Performance:
+51.26%
1-Day Range:
$3.00
$3.195
1-Week Range:
$2.905
$3.38
52-Week Range:
$1.26
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.01 | 490.79M | 0 | -175.43M | -143.28M | -1.9736 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
CABA - Finviz
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D - Business Wire
CABA: Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption - TradingView
CABA: Rese-cel shows durable, safe, drug-free responses, enabling rapid outpatient adoption and expansion - TradingView
Cabaletta Bio Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases - Yahoo Finance
Jennison Associates LLC Increases Stake in Cabaletta Bio Inc - GuruFocus
Investors’ Stock Portfolio: Top 5 Penny Stocks To Buy - Insider Monkey
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
CABALETTA BIO INC (CABA) Stock Chart - ChartMill
Jennison Associates (NASDAQ: CABA) holds 24.27M shares, 11.4% - Stock Titan
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio reports phase 1/2 data for autoimmune therapy - Investing.com UK
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data By Investing.com - Investing.com South Africa
CABA: Cabaletta Bio Shares Positive Clinical Updates at EULAR 20 - GuruFocus
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path - TipRanks
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data - Investing.com India
Cabaletta Bio reports phase 1/2 data for autoimmune therapy By Investing.com - Investing.com Nigeria
Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - The Manila Times
Cabaletta Bio Shares Tick Up Ahead of June Data Investors Await - Bez Kabli
Cabaletta Bio (CABA) Climbs 2.7% as Biotech Stock Tests Key Resistance Near $4.14Low Risk Entry Stocks - thelegaladvocate.com
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
CABA Technical Analysis | Trend, Signals & Chart Patterns | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
CABA stock on track for best day in 6 months after positive early results from cell therapy trial - MSN
Cabaletta Reports Drug-Free Responses in CAR-T Study - MyChesCo
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - sharewise.com
Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Inc (CABA) Stock Price, Quote, News & History - Benzinga
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
CABA Maintains Rating by Wells Fargo -- Price Target Raised to $4.00 - GuruFocus
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $16 to $16 - Moomoo
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $3.61 - Moomoo
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Key facts: Cabaletta Q1 $0.39 Adj Loss, $43.52M Net Loss; ASGCT Data - TradingView
CABA Shows Promising Results in New Clinical Data - GuruFocus
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):